Cybin Inc (CYBN) Stock Price, Quote & News

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology

Sector: Healthcare

Website: cybin.com

Address:

100 King Street West, Suite 5600, Toronto, Canada

HedgeAlerts Nov. 23 at 3:42 AM

Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.28 - $0.30 Exit Price Target: $0.43 Profit Margin: +54% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

LiquidThetaOptions Nov. 22 at 2:26 PM

💎 LiquidTheta® Live Actionable Trade Asset: $CYBN Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $1.52- $1.86 Scale out: $5.91-$10.12 Profit Potential : 64% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

HughJasol Nov. 21 at 11:15 PM

$CYBN wow.. this might not get back to 6…

0 · Reply

HedgeAlerts Nov. 21 at 11:05 PM

0 · Reply

everup Nov. 21 at 9:12 PM

$CYBN piece of flaming turd...if I break even I'd be more than happy

0 · Reply

Bbbb44444 Nov. 21 at 6:20 PM

$CYBN How’s everyone doing?

1 · Reply

PsychedStocks Nov. 21 at 5:09 PM

$CYBN regardless of the current market, I think public interest in psychedelics will have another rapid expansion in the next year.

2 · Reply

kev90123 Nov. 21 at 4:26 PM

$CYBN

0 · Reply

everup Nov. 21 at 3:40 PM

$CYBN checking in on this turd...oh great all time lows coming in...what are we at, 10 cents?

0 · Reply

PsychedStocks Nov. 21 at 2:51 PM

$CYBN happy when people share their experiences with psychedelics and how it changed their lives. If you have any good stories let’s hear them!

1 · Reply

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 7:20 AM EST - 9 days ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:30 AM EST - 10 days ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:30 AM EST - 16 days ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 5, 2025, 7:30 AM EST - 17 days ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:30 AM EST - 19 days ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Oct 31, 2025, 4:19 PM EDT - 22 days ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 25 days ago

Cybin Announces $175 Million Registered Direct Offering

Oct 21, 2025, 8:00 AM EDT - 4 weeks ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Sep 23, 2025, 5:00 PM EDT - 2 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 11, 2025, 3:59 PM EDT - 2 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 7:30 AM EDT - 2 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 4, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 2 months ago

Cybin Announces Senior Leadership Changes

Aug 26, 2025, 7:30 AM EDT - 3 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 18, 2025, 5:30 PM EDT - 3 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Aug 13, 2025, 5:30 PM EDT - 3 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 7, 2025, 7:30 AM EDT - 3 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 6, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 17, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 1, 2025, 11:19 AM EDT - 5 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 10:03 PM EDT - 5 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 9:27 PM EDT - 5 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 13, 2025, 7:45 AM EDT - 5 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 12, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 11, 2025, 7:30 AM EDT - 5 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 3, 2025, 7:30 AM EDT - 6 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

May 22, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 20, 2025, 7:30 AM EDT - 6 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 15, 2025, 7:30 AM EDT - 6 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 14, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 8, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 1, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Apr 23, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 21, 2025, 8:00 AM EDT - 7 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Feb 10, 2025, 9:48 PM EST - 10 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Jan 15, 2025, 12:07 PM EST - 11 months ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 13, 2025, 7:30 AM EST - 11 months ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 9, 2025, 5:00 PM EST - 11 months ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 10, 2024, 7:30 AM EST - 1 year ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 4, 2024, 7:30 AM EST - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Nov 18, 2024, 7:00 AM EST - 1 year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 14, 2024, 7:30 AM EST - 1 year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

HedgeAlerts Nov. 23 at 3:42 AM

0 · Reply

LiquidThetaOptions Nov. 22 at 2:26 PM

0 · Reply

HughJasol Nov. 21 at 11:15 PM

$CYBN wow.. this might not get back to 6…

0 · Reply

HedgeAlerts Nov. 21 at 11:05 PM

0 · Reply

everup Nov. 21 at 9:12 PM

$CYBN piece of flaming turd...if I break even I'd be more than happy

0 · Reply

Bbbb44444 Nov. 21 at 6:20 PM

$CYBN How’s everyone doing?

1 · Reply

PsychedStocks Nov. 21 at 5:09 PM

$CYBN regardless of the current market, I think public interest in psychedelics will have another rapid expansion in the next year.

2 · Reply

kev90123 Nov. 21 at 4:26 PM

$CYBN

0 · Reply

everup Nov. 21 at 3:40 PM

$CYBN checking in on this turd...oh great all time lows coming in...what are we at, 10 cents?

0 · Reply

PsychedStocks Nov. 21 at 2:51 PM

$CYBN happy when people share their experiences with psychedelics and how it changed their lives. If you have any good stories let’s hear them!

1 · Reply

HedgeAlerts Nov. 20 at 11:17 PM

Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.21 - $0.30 Exit Price Target: $0.35 Profit Margin: +67% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Alex1710 Nov. 20 at 7:12 PM

$CYBN I am not shareholder yet. I have a list of 12 stocks involved in psychedelic. Atai Beckley seems a very good stock(maybe overvalued by now) just like Cybin. I have to admit it is not easy to make a choice between all those companies.

1 · Reply

Alex1710 Nov. 20 at 7:06 PM

$CYBN I am a big believer in psychedelic drug. I think one day they will replace what's on the market now. That acts quickly very effectively and side effects are inexistant. Above all no addiction.

0 · Reply

anachartanalyst Nov. 20 at 5:02 PM

$CYBN https://anachart.com/wp-content/uploads/ana_temp/1763658126_soc-img.jpg

0 · Reply

JarvisFlow Nov. 20 at 4:02 PM

Canaccord Genuity has adjusted their stance on Cybin ( $CYBN ), setting the rating to Buy with a target price of 70 → 45.

1 · Reply

PsychedStocks Nov. 20 at 3:49 PM

$CYBN best IP in the sector imo

1 · Reply

LiquidThetaOptions Nov. 20 at 3:00 PM

0 · Reply

microdoseme Nov. 20 at 2:54 PM

$CYBN Bbbb44444 In your dreams.....everyone knows we have a superior product.

1 · Reply

Bbbb44444 Nov. 20 at 2:50 PM

$CYBN ATAI should just send a lowball offer to buyout this hot garbage.

0 · Reply

HedgeAlerts Nov. 20 at 7:19 AM

Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.21 - $0.22 Exit Price Target: $0.33 Profit Margin: +56% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

HedgeAlerts Nov. 19 at 9:05 PM

Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.21 - $0.30 Exit Price Target: $0.31 Profit Margin: +47% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Rico_Again_Jorge Nov. 19 at 8:49 PM

$CYBN Oh god still a pOS

0 · Reply

Market Cap	140.80M
Revenue (ttm)	0.00
Net Income (ttm)	-81.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	621,700
Avg Vol	860,020
Day's Range	N/A - N/A
Shares Out	25.19M
Stochastic %K	7%
Beta	0.66
Analysts	Strong Sell
Price Target	$43.20